Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ViewRay, Inc is a medical devices business based in the US. ViewRay shares (VRAY) are listed on the NASDAQ and all prices are listed in US Dollars. ViewRay employs 309 staff and has a trailing 12-month revenue of around USD$55 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Mobile users
52-week range | USD$1.1055 - USD$7.36 |
---|---|
50-day moving average | USD$4.5883 |
200-day moving average | USD$3.387 |
Wall St. target price | USD$5.88 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.213 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$55 million |
---|---|
Gross profit TTM | USD$2.4 million |
Return on assets TTM | -26.3% |
Return on equity TTM | -90.39% |
Profit margin | -212.65% |
Book value | $1.021 |
Market capitalisation | USD$808.2 million |
TTM: trailing 12 months
There are currently 13.3 million ViewRay shares held short by investors – that's known as ViewRay's "short interest". This figure is 2.3% down from 13.6 million last month.
There are a few different ways that this level of interest in shorting ViewRay shares can be evaluated.
ViewRay's "short interest ratio" (SIR) is the quantity of ViewRay shares currently shorted divided by the average quantity of ViewRay shares traded daily (recently around 1.3 million). ViewRay's SIR currently stands at 10.4. In other words for every 100,000 ViewRay shares traded daily on the market, roughly 10400 shares are currently held short.
However ViewRay's short interest can also be evaluated against the total number of ViewRay shares, or, against the total number of tradable ViewRay shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ViewRay's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 ViewRay shares in existence, roughly 90 shares are currently held short) or 0.1312% of the tradable shares (for every 100,000 tradable ViewRay shares, roughly 131 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ViewRay.
Find out more about how you can short ViewRay stock.
We're not expecting ViewRay to pay a dividend over the next 12 months.
ViewRay's shares were split on 8 July 2015.
Over the last 12 months, ViewRay's shares have ranged in value from as little as $1.1055 up to $7.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ViewRay's is 1.0341. This would suggest that ViewRay's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.